MannKind | MNKD - Umsatzkosten





Umsatzkosten Veränderung Datum
Adma Biologics USD 33.74M 16.65M 2026-03
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Insmed USD 69.29M 19.79M 2026-06
Karyopharm Therapeutics USD 1.34M 139K 2026-03
MacroGenics USD 9.53M 585K 2026-03
MannKind USD 34.21M 5.38M 2026-06
Merck USD 3.14B 200M 2026-06
Minerva Neurosciences 386K 31K 2024-06
Novavax USD 22.1M 608K 2025-12
Novo Nordisk DKK 2.66B 10.94B 2026-06
Pfizer USD 4.09B 498M 2026-06
Sanofi EUR 3.02B 656M 2026-06
Xencor USD 61.66M 50.95M 2025-06